Evidence map›Paper›PMID 39775109›Full record

ArticleJournal of neurology2025

Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy.

Eva Maria Kesenheimer, Maria Janina Wendebourg, Claudia Weidensteiner, Laura Sander, Matthias Weigel, Tanja Haas, Dirk Fischer, Christoph Neuwirth, Nathalie Braun, Markus Weber and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eva Maria KesenheimerDepartment of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland.
Maria Janina WendebourgDepartment of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland.
Claudia WeidensteinerDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Laura SanderDepartment of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland.
Matthias WeigelTranslational Imaging in Neurology (ThINk), Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Tanja HaasDivision of Radiological Physics, Department of Radiology, University Hospital Basel, Basel, Switzerland.
Dirk FischerDivision of Neuropediatrics and Developmental Medicine, University Childrens` Hospital of Basel (UKBB), University of Basel, Basel, Switzerland.
Christoph NeuwirthNeuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Nathalie BraunNeuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Markus WeberNeuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Cristina GranzieraDepartment of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland.
Michael SinnreichDepartment of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland.
Oliver BieriDivision of Radiological Physics, Department of Radiology, University Hospital Basel, Basel, Switzerland.
Regina SchlaegerDepartment of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland. regina.schlaeger@usb.ch.ORCID http://orcid.org/0000-0003-2056-5765

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the approval of disease-modifying treatments for 5q-spinal muscular atrophy (SMA), there is an increasing need for biomarkers for disease course and therapeutic response monitoring. Radially sampled Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA) MR-imaging enables spinal cord (SC) gray matter (GM) delineation and quantification in vivo. This study aims to assess SC GM atrophy in patients with 5q-SMA and its associations with clinical disability.

methodsTwenty-one patients with 5q-SMA and twenty-one age- and sex-matched healthy controls (HCs) prospectively underwent 3 T axial 2D-rAMIRA MR-imaging at the intervertebral disc levels C2/C3-C5/C6 and T

resultsCompared to HCs, patients had significantly reduced SC GM areas at levels C3/C4 (relative reduction (RR) = 13.6%, p < 0.0001); C4/C5 (RR = 16.7%, p < 0.0001), C5/C6 (RR = 17.1%, p < 0.0001), and T

conclusionSC GM atrophy is detectable in patients with 5q-SMA and is consistently associated with clinical measures of upper limb function, physiotherapeutic assessments, and SMA-FRS indicating the clinical relevance of the observed atrophy. Further longitudinal investigations are necessary next steps to evaluate this novel and easily applicable imaging marker as a potential disease course and therapeutic response marker.

Indexed as

Gray MatterMagnetic Resonance ImagingMuscular Atrophy, SpinalAdolescentAdultAtrophyFemaleHumansMaleMiddle AgedMuscle StrengthSpinal CordYoung AdultMagnetic resonance imagingSMASpinal cord atrophySpinal cord imagingSpinal muscular atrophy

Identifiers

PMID39775109
PMCPMC11706851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.